CY1111088T1 - PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY - Google Patents

PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY

Info

Publication number
CY1111088T1
CY1111088T1 CY20101101027T CY101101027T CY1111088T1 CY 1111088 T1 CY1111088 T1 CY 1111088T1 CY 20101101027 T CY20101101027 T CY 20101101027T CY 101101027 T CY101101027 T CY 101101027T CY 1111088 T1 CY1111088 T1 CY 1111088T1
Authority
CY
Cyprus
Prior art keywords
controlled
tolterodin
liberty
administration
pharmaceutical form
Prior art date
Application number
CY20101101027T
Other languages
Greek (el)
Inventor
Lisbeth Nilvebrant
Bengt Hallén
Birgitta Olsson
Jan Strömbom
Bo KREILGÅRD
Jacobsen Lene Orup
Ulla Hoeck
Helle Kristensen
Torkel Gren
Anders Ringberg
Martin Wikberg
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111088(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/en
Priority claimed from SE9803871A external-priority patent/SE9803871D0/en
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of CY1111088T1 publication Critical patent/CY1111088T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Μέθοδος και τυποποίηση για θεραπεία ασταθούς ή υπερδραστικής ουροδόχου κύστης, όπου τολτεροδίνη ή σχετική με τολτεροδίνη ένωση ή φαρμακευτικώς αποδεκτό άλας αυτής χορηγείται σε έναν ασθενή σε μια φαρμακευτικώς αποτελεσματική ποσότητα αυτής μέσω φαρμακοτεχνικής μορφής ελεγχόμενης απελευθέρωσης που χορηγεί τολτεροδίνη ή την εν λόγω σχετική με τολτεροδίνη ένωση ή άλας αυτής με ελεγχόμενο ρυθμό για τουλάχιστον 24 ώρες.Method and formulation for the treatment of unstable or hyperactive bladder, wherein tolterodine or a tolterodine related compound or a pharmaceutically acceptable salt thereof is administered to a patient in a pharmaceutically effective amount thereof by a controlled release formulation administering the drug or drug. salt thereof at a controlled rate for at least 24 hours.

CY20101101027T 1998-08-27 2010-11-17 PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY CY1111088T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (en) 1998-08-27 1998-08-27 Transdermally administered tolterodine as an antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (en) 1998-11-11 1998-11-11 Therapeutic method and formulation
EP99946521A EP1039882B1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Publications (1)

Publication Number Publication Date
CY1111088T1 true CY1111088T1 (en) 2015-06-11

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101027T CY1111088T1 (en) 1998-08-27 2010-11-17 PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY

Country Status (31)

Country Link
US (1) US6770295B1 (en)
EP (2) EP2153825A1 (en)
CN (1) CN1239152C (en)
AP (1) AP1529A (en)
AR (1) AR029311A1 (en)
AT (1) ATE487471T1 (en)
AU (1) AU745190B2 (en)
BG (1) BG65168B1 (en)
CA (1) CA2311755C (en)
CY (1) CY1111088T1 (en)
CZ (1) CZ302630B6 (en)
DE (1) DE69942928D1 (en)
DK (1) DK1039882T3 (en)
EA (1) EA002720B1 (en)
GE (1) GEP20043354B (en)
HK (1) HK1034664A1 (en)
HU (1) HUP0100437A3 (en)
ID (1) ID25824A (en)
IL (1) IL136294A (en)
IS (1) IS2976B (en)
ME (1) ME00850B (en)
MY (1) MY127946A (en)
NO (1) NO329830B1 (en)
NZ (1) NZ504618A (en)
OA (1) OA11636A (en)
PT (1) PT1039882E (en)
SI (1) SI1039882T1 (en)
SK (1) SK287111B6 (en)
TR (1) TR200001998T1 (en)
UA (1) UA72882C2 (en)
WO (1) WO2000012069A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (en) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermal therapeutic system (TTS) containing tolterodine
DE19932651A1 (en) * 1999-07-13 2001-01-18 Hexal Ag Transdermal therapeutic system for the application of tolterodine
CA2387973C (en) * 1999-11-11 2009-12-22 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE10149674A1 (en) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CA2466336A1 (en) * 2001-11-09 2003-05-15 Ebrahim Versi Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
KR20050085563A (en) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 Alpha-2-delta ligand to treat lower urinary tract symptoms
JP2006515607A (en) * 2003-01-22 2006-06-01 ファイザー・ヘルス・アクチエボラーグ Reduced dose of tolterodine and other antimuscarinic agents to treat urinary disorders
DE10315917A1 (en) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Highly pure bases of 3,3-diphenylpropylamine monoesters
WO2004105735A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
ES2359375T3 (en) 2003-11-04 2011-05-20 Supernus Pharmaceuticals, Inc. DOSAGE FORMS OF DAILY SINGLE DOSE OF TROSPIO.
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
CN1330297C (en) * 2005-07-04 2007-08-08 宛六一 Tolterodine tartrate soft capsule and its preparing method
KR20070012205A (en) * 2005-07-22 2007-01-25 주식회사종근당 Stable controlled-release pellet containing tolterodine
DK1993559T3 (en) 2006-02-03 2016-10-03 Opko Renal Llc Treatment of vitamin D deficiency and MALFUNCTION with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
ES2670029T3 (en) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D replenishment agent and vitamin D hormone replacement agent
DK2481400T3 (en) 2007-04-25 2014-09-29 Opko Ip Holdings Ii Inc Controlled-release oral preparations comprising a vitamin D compound and a waxy carrier
EP3225243A1 (en) 2007-04-25 2017-10-04 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101495578B1 (en) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 Method of treating vitamin d insufficiency and deficiency
EP2173329A1 (en) * 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
ES2954932T3 (en) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Useful methods, compositions, uses and kits for vitamin D deficiency and related disorders
TWI630208B (en) 2008-12-08 2018-07-21 歐陸斯迪公司 Dihydroetorphine
KR101004205B1 (en) * 2008-12-17 2010-12-24 동아제약주식회사 The controlled released pharmaceutical compsitions of udenafil for sustained release property
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (en) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 Composition with improved skin penetration for transdermal delivery of tolterodine
CN105796530A (en) 2010-03-29 2016-07-27 赛特克罗公司 Methods and compositions for reducing parathyroid levels
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (en) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermal administration of memantine
JP5642790B2 (en) * 2010-08-03 2014-12-17 久光製薬株式会社 Patch and method for enhancing its adhesive strength
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
IL290855B2 (en) 2016-03-28 2024-06-01 Eirgen Pharma Ltd Methods of vitamin d treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
SE8800207D0 (en) 1988-01-22 1988-01-22 Kabivitrum Ab NEW AMINES, THEIR USE AND MANUFACTURING
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
CA2132865C (en) 1992-05-13 2003-12-02 Eun S. Lee Transdermal administration of oxybutynin
SE9203318D0 (en) 1992-11-06 1992-11-06 Kabi Pharmacia Ab NOVEL 3,3-DIPHENYL PROPYLAMINES, THEIR USE AND PREPARATION
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
WO1996012477A1 (en) 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
EP0924983A4 (en) 1996-07-19 1999-08-25 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
JP2001502302A (en) * 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション How to treat urinary incontinence

Also Published As

Publication number Publication date
AR029311A1 (en) 2003-06-25
HUP0100437A2 (en) 2002-05-29
NO329830B1 (en) 2011-01-03
ATE487471T1 (en) 2010-11-15
SK287111B6 (en) 2009-12-07
CZ302630B6 (en) 2011-08-10
CZ20001924A3 (en) 2001-04-11
UA72882C2 (en) 2005-05-16
CA2311755A1 (en) 2000-03-09
HK1034664A1 (en) 2001-11-02
EA200000468A1 (en) 2000-12-25
IL136294A (en) 2004-02-08
CA2311755C (en) 2010-03-23
AU745190B2 (en) 2002-03-14
EA002720B1 (en) 2002-08-29
AU5891899A (en) 2000-03-21
BG104476A (en) 2000-12-29
AP1529A (en) 2006-01-03
ME00850B (en) 2008-08-07
NZ504618A (en) 2002-09-27
SI1039882T1 (en) 2011-01-31
IL136294A0 (en) 2001-05-20
WO2000012069A1 (en) 2000-03-09
EP2153825A1 (en) 2010-02-17
AP2000001823A0 (en) 2000-06-30
DK1039882T3 (en) 2011-01-24
TR200001998T1 (en) 2001-01-22
EP1039882A1 (en) 2000-10-04
IS2976B (en) 2017-07-15
US6770295B1 (en) 2004-08-03
HUP0100437A3 (en) 2002-08-28
MY127946A (en) 2007-01-31
OA11636A (en) 2004-09-03
EP1039882B1 (en) 2010-11-10
GEP20043354B (en) 2004-04-13
IS5537A (en) 2000-06-15
SK7492000A3 (en) 2001-02-12
NO20002977D0 (en) 2000-06-09
DE69942928D1 (en) 2010-12-23
ID25824A (en) 2000-11-09
PT1039882E (en) 2011-01-03
BG65168B1 (en) 2007-05-31
CN1239152C (en) 2006-02-01
CN1287484A (en) 2001-03-14
NO20002977L (en) 2000-06-09

Similar Documents

Publication Publication Date Title
CY1111088T1 (en) PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY
ATE306266T1 (en) IMPROVED ADMINISTRATION TECHNOLOGY FOR MULTIPLE MEDICATION DOSAGE
NO20022014L (en) A solid oral controlled release dosage form containing hydrocodone
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
ES2170069T3 (en) 1-ALFA-HYDROXIPREVITAMINE D FOR ORAL ADMINISTRATION.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU94046316A (en) Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment
CY1105707T1 (en) COMBINATIONS OF FORMOTEROL AND A TRIOTROP SALT
DK0503440T3 (en) Sumatriptan-containing medicines
BR9408378A (en) Pharmaceutically acceptable salt compound Pharmaceutical composition and processes for treating a patient who has suffered a stroke and suffering from a condition of progressive loss of central nervous system function and to improve the side effects caused in a patient by antineoplastic treatment of the disease it produces oxidative damage
ATE108657T1 (en) PHARMACEUTICAL FORMULATION CONTAINING GALANTHEMIN FOR THE TREATMENT OF ALCOHOLISM.
IT1196564B (en) USE OF ACETYL L-CARNITINE IN THE THERAPEUTIC TREATMENT OF PERIPHERAL NEUROPATHIES
DK0754034T3 (en) Effervescent pharmaceutical formulations containing biodegradable controlled release microcapsules
KR970025615A (en) Cancer metastasis inhibitor
DE69824313D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SIBUTRAMINE AND ORLISTAT
IT1244636B (en) USE OF ACETYL L-CARNITINE IN THERAPEUTIC TREATMENT OF COMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT.
KR910018348A (en) Sulfonylamino substituted bicyclo cyclic hydroxamic acid derivative
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
RU2004112422A (en) ROUVASTATIN IN PREDEDENTIONAL CONDITIONS
KR930702985A (en) Treatment of Esophageal Cancer
KR890015743A (en) Use of TP-receptor antagonist to improve the action of myofibroblasts
LV11524A (en) Use of benzidamine as a treatment for pathological conditions induced by TNF
KR930019207A (en) Use of L-carnitine for the treatment of carnitine deficient HIV-serum positive patients
RU2006137657A (en) USE OF CAMPTOTECINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES USING A FIXED DOSE TREATMENT SCHEME
EE200100193A (en) Use of 3- (1H-imidazol-4-ylmethyl) -indan-5-ol in the manufacture of a medicament for intraspinal, intra-tea or epidural administration